GSK3B and non-small cell lung carcinoma: Cytoplasmic GSK-3β inhibition in A549 cells may activate the Wnt/β-catenin signal and upregulate survivin expression, possibly leading to resistance to cisplatin (CDDP) in NSCLC cells [62].